DPP4 and metabolic syndrome: Including regulating the levels of adenosine monophosphate-activated protein kinase and adiponectin levels in MetS mice, reducing inflammatory response and fatty liver (137), DPP-4/incretin axis reducing cardiovascular events (138), and improving hyperglycemia induced vascular lesions through endothelium-dependent Manner (139).